News | December 05, 2022
Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
Acquisition expands Merck’s growing hematology portfolio
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
He has over 23 years' experience working in leading companies such as Omniactive Health Technologies, Johnson Matthey Chemicals, BASF, Godrej Agrovet Limited & Bharat Petroleum Corporation Limited.
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Subscribe To Our Newsletter & Stay Updated
